Predictive factors of improved postoperative results after surgery for patients with hepatocellular carcinoma: A retrospective study

Keywords
prognosis, hepatocellular carcinoma, nomogram, long-term survival, OS, FRS

Abstract
Introduction
Several clinical studies have demonstrated the benefits of surgery for patients with hepatocellular carcinoma .The goal of our study was to identify prognostic factors associated with overall survival and recurrence-free survival in patients with HCC

Material and methods
We retrospectively conducted follow-up evaluations of 176 patients with HCC up to 10 years after resection. All of enrolled patients were divided into two groups: those who survived less than 3 years and those who survived more than 3 years.Independent prognostic factors associated with OS and RFS were determined via uni,multi Cox model. Two prognostic nomogram models were built on the basis of the data and evaluated via the concordance index.The calibration curves indicated that the two nomograms performed well over 5-year. Additionally,area under the receiver operating characteristic curve and the time-dependent area under the ROC curve (AUC) were determined,decision curve analyses were conducted

Results
The nomograms successfully discriminated HCC patients. Prognostic factors for OS and RFS were identified, and nomograms were successfully built.calibration discrimination was good, prediction models (C-indexes: 0.815 and 0.80, respectively).Our nomograms and calibration curves demonstrated favorable results with strong predictive accuracy and ROC curves, and according to the DCA, our nomogram results showed greater net clinical benefit. The KM plots for OS and RFS were generated via the log-rank test, the P value of which was <0.001. Ultimately.

Conclusions
We established nomogram survival prediction models to predict the prognosis of HCC after invasive treatment and achieved an acceptable level of accuracy in both OS and RFS analyses.These guiding clinical treatment strategies.

Preprint

Predictive factors of improved postoperative results after surgery for patients with hepatocellular carcinoma: A retrospective study

Abstract: Background: Several clinical studies have demonstrated the benefits of surgery for patients with hepatocellular carcinoma (HCC). The goal of our study was to identify prognostic factors associated with overall survival (OS) and recurrence-free survival (RFS) in patients with HCC and develop nomograms to predict these factors.

Methods: We retrospectively conducted follow-up evaluations of 176 patients with HCC up to 10 years after their tumors were removed. All of these patients were from a single hospital, and all of the enrolled patients were divided into two groups: those who survived less than 3 years and those who survived more than 3 years. Independent prognostic factors associated with OS and RFS were determined via univariate and multivariate Cox regression model analyses. Two prognostic nomogram models were built on the basis of the data and evaluated via the concordance index (C-index). The calibration curves indicated that the two nomograms performed well over a 5-year period. Additionally, the area under the receiver operating characteristic (ROC) curve and the time-dependent area under the ROC curve (AUC) were determined, and decision curve analyses (DCAs) were conducted.

Results: The nomograms successfully discriminated patients with HCC. Prognostic factors for OS and RFS were identified, and nomograms were successfully built. The calibration discrimination was good for both the OS and RFS nomogram prediction models (C-indexes: 0.815 and 0.80, respectively). Our nomograms and calibration curves demonstrated favorable results with strong predictive accuracy and ROC curves, and according to the DCA, our nomogram results showed greater net clinical benefit. The Kaplan–Meier plots for OS and RFS were generated via the log-rank test, the P value of which was <0.001. Ultimately, the nomograms successfully discriminated patients with HCC.

Conclusions: We established nomogram survival prediction models to predict the prognosis of HCC after invasive treatment and achieved an acceptable level of accuracy in both OS and RFS analyses. These models may be valuable for guiding the selection of clinical treatment strategies and may also facilitate clinical decision making.

Keywords: hepatocellular carcinoma; nomogram; prognosis; OS; FRS; long-term survival

1. Introduction

Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for approximately 90% of these cases [1]. Liver cancer is the sixth most commonly diagnosed cancer and ranks as the third leading cause of cancer-related death worldwide. Furthermore, its incidence rates have been increasing rapidly. Approximately 700,000 patients are diagnosed globally each year [2,3]. Hepatectomy, the most promising treatment for patients, is accepted as the gold standard therapeutic option for patients with small HCC nodules. However, most patients who are diagnosed at an advanced stage miss the opportunity for surgical resection [4].

Despite high recurrence rates, some studies have reported recurrence rates as high as 60–80% within 5 years of resection; the overall survival rate is approximately 40–60%, and the disease-free survival rate is between 20% and 60% after 5 years [5–8]. Therefore, HCC recurrence can adversely impact long-term survival outcomes as well as patient quality of life [9]. The highest mortality rates and incidences of HCC have been observed in Southeast Asia and Northwest Africa [10].

Several prognostic schemes, such as the American Joint Committee on Cancer (AJCC TNM), Barcelona Clinic Liver Criteria (BCLC), Japan Integrated Staging Score (JIS score), and Cancer of the Liver Italian Program (CLIP), have been developed to identify prognostic factors [11–13].

Recently, studies have attempted to predict outcomes utilizing the primary characteristics of the disease [14,15]. Many factors associated with HCC recurrence, such as tumor stage, large tumor size, portal vein tumor thrombus, hepatitis B surface antigen (HBsAg), hepatitis B virus-DNA (HBV-DNA) and alpha-fetoprotein (AFP) levels, have been identified [7,16,17]. Additionally, most of those studies have focused on identifying factors associated with an increased risk of tumor recurrence rather than entering the risk factors into multipredictor models that consider their joint effects.

Furthermore, it is important to identify prognostic factors associated with survival prior to treatment. However, only a few studies have integrated these factors into a nomogram to predict patient prognosis [18,19]. In this study, we aimed to identify prognostic factors to develop a prediction model and identify clinicopathological variables that are associated with long-term survival. Thus, a nomogram model that can estimate individualized long-term overall survival following treatment is needed.

2. Methods

2.1. Study Population and Patients

The selection procedure and study design are shown in Figure 1. We retrospectively analyzed 180 consecutive patients who had clinicopathological characteristics consistent with having HCC at our hospital from January 2010 to December 2021.

Preprint

Among the 180 patients, 1 **(0.5%)** died before surgery, and 3 (1.6%) patients were lost to follow-up. The inclusion criteria were as follows: (1) patients older than 30 confirmed with HCC, (2) no history of other diseases, and (3) no previous treatment for HCC before surgery. These patients were grouped into 2 different cohorts: a short-term survivor group, which included patients who survived for less than 3 years after surgical resection, and a long-term survivor group, which included patients who survived longer than 3 years after resection. The type of operation was determined by a multidisciplinary team (MDT), and all the surgeons had extensive liver surgery experience.Figure 1.

2.2. Clinicopathologic Variables

Baselines for standard demographics, preoperative data, operative and pathological characteristics, and postoperative data were retrospectively reviewed. The demographic data included age, sex (male or female), follow-up, disease recurrence, tumor stage, lymph node metastasis, tumor size and histopathological grading and were categorized on the basis of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM guidelines. The tumor (T) stage, lymph node (N) status, TNM status and overall survival were retrieved from the patients' hospital records. The following characteristics were included: hepatitis B virus (HBsAb, HBeAg), hepatitis C virus (HCV), AFP, CEA, CA19-9, CA-125 and ferritin on the basis of their previously suggested associations with HCC recurrence. The pathological data included tumor size, tumor number, cirrhosis status, tumor stage (I, II, III and IV), macrovascular invasion (present or absent), and resection margin status (negative or positive). Recurrences were also documented.

2.3. Follow-Up

We examined the patients every 3 to 6 months for the first two years after hospital discharge and every 6 months thereafter. The follow-up evaluation included a physical examination, chest radiography, and blood examination, which included analyses of tumor markers (abdominal ultrasound, multiphasic CT or MRI, liver function tests, AFP measurements, CA-125 measurements).

Recurrence was diagnosed on the basis of physical examinations, diagnostic imaging results, and tumor markers. The date of recurrence was defined as the time that elapsed between the date of primary liver resection and the date that evidence of recurrence was confirmed by a physician.

2.4. Statistical Analysis

The primary endpoint was overall survival (OS), which was calculated from the date of resection to the date of death or the last follow-up investigation and analyzed via the Kaplan–Meier method.

Recurrence-free survival (RFS) was calculated from the date of resection to the date of disease progression, last follow-up investigation, or death.

Kaplan–Meier survival curves were used to assess OS and RFS. These data are reported herein as medians with 95% confidence intervals (95% CIs). Differences were considered statistically significant if the *p* value was lower than 0.05 according to the log-rank test.

To identify the prognostic factors related to OS and RFS, multivariate analysis was performed via the Cox regression hazard model for statistically significant variables in the univariate analysis and to identify the associations between potentially important clinical factors and long-term survival after HCC resection.

After the importance of all independent variables was evaluated through the univariate Cox regression hazard model, significant variables ($P < 0.05$) were extracted and included in the multivariate Cox regression hazard models for further analysis. The data are presented with hazard ratios (HRs) and 95% confidence intervals (CIs). Multivariate Cox regression analysis was employed to identify the final risk factors ($P < 0.05$) for establishing a nomogram to predict the risk of HCC. Prognostic factors identified in the multivariate Cox regression analysis were used to establish a nomogram to predict OS and RFS between 1 and 5 years after surgery. To evaluate the predictive performance of the nomogram, Cox regression analysis was performed with the R package version 4.3.3 to calculate the C-index and develop calibration curves. Random OS and RFS forest plots were generated to identify the importance of the variables.

All the data were analyzed via SPSS 27.0 and R package version 4.3.3 (R Foundation for Statistical Computing, Vienna, Austria). Two-sided P values were considered statistically significant if $P < 0.05$.

3. Results

3.1. Baseline Characteristics of the Patient Cohort

After applying the eligibility criteria, the final study population consisted of 176 patients. Details of the flow diagram are presented in Figure 1. The median overall survival was 43 months (range: 4–82 months), and the median recurrence-free survival was 39 months (range: 2–75 months). The median follow-up was 66 months for patients who survived at the end of the study. Kaplan–Meier analysis revealed that the 1-, 3-, 5-, and 10-year overall survival rates were 98.9%, 77.1%, 55.9%, and 43.1%, respectively (Figure 2). Furthermore, the 1-, 3-, 5-, and 10-year RFS rates were 82.9%, 41.0%, 23.3%, and 18.5%, respectively (Figure 3). After the exclusion of 4 patients who either died before the operation or were lost to follow-up, 176 patients were included in the comparative analyses. Among these 176 patients, 48 (27.3%) patients survived ≤ 3 years and were sorted into the short-term survival group. The remaining 128 (72.7%) patients survived for > 3 years and were designated as the long-term survival group. The baseline patient characteristics are displayed in Table 1.

Regarding patient characteristics, the majority of variables were similar between the two groups. However, there were significant differences in age ($p=0.002$), BMI ($p=0.016$), smoking status ($p=0.042$), tumor stage ($p<0.001$), serum albumin levels ($p=0.001$), and CA-125 concentrations ($p=0.026$).

Preprint

Both OS and RFS were significantly different (p<0.001). The histopathological findings and resection margins were also compared between patients in the two groups (Table 2). The short- to long-term survival group had significantly greater values for the following variables: tumor size (p<0.001), tumor number (p<0.001), recurrence (p<0.001), hospital stay (p=0.005), and presence of portal vein thrombus (p<0.001).

3.2. Univariate and Multivariate Analysis of Survival Outcomes and Predictive Factors

Since long-term survival is rather poor in patients with HCC, one goal of this investigation was to determine the impact of various variables on long-term OS. A logistic regression analysis with iterative backward and forward testing was employed with the following variables as the input: age at the time of operation, sex, underlying liver disease (such as smoking and alcohol use) and preoperative and postoperative outcomes. Several factors were identified as being significantly different between the ≤ 3-year survivors and the >3-year survivors in the univariate analysis of overall survival via Cox regression model analysis. These factors included: age: HR: 1.059, 95.0% confidence interval [CI]: 1.037-1.083 (p<0.001), BMI: HR: 0.917, 95.0% [CI]: 0.852-0.987 (p=0.022), HBc-IgM: HR: 0.238, 95.0% [CI]: 0.112-0.504 (p<0.001), albumin: HR: 0.931, 95.0% [CI]: 0.892-0.972 (p=0.001), AFP: HR: 1.0, 95.0% [CI]: 1.0-1.0 (p=0.059), CA19-9: HR: 1.003, 95.0% [CI]:1.002-1.005 (p<0.001), CA-125: HR: 1.005, 95.0% [CI]: 1.001-1.008 (p=0.01), tumor size: HR: 1.238, 95.0% [CI]: 1.172-1.308 (p<0.001), multiple tumors: HR: 4.294, 95.0% [CI]: 2.750-6.705 (p<0.001), tumor stage: HR: 2.76, 95.0% [CI]: 0.273-2.132 (p<0.001), recurrence: HR: 0.600, 95.0% [CI]: 0.472-0.762 (p<0.001) MVI (M1/M2/M3): HR: 17.107, 95.0% [CI]: 2.189-133.6 (p=0.002)**,** Metastasis: HR: 0.510, 95.0% [CI]: 0.285-0.912 (p=0.023).
On the other hand, the multivariate OS analysis factors were as follows: age: HR: 1.043, 95.0% CI: 1.018-1.069 (p<0.001), BMI: HR: 0.884, 95.0% [CI]: 0.807-0.969 (p=0.009), HBc-IgM: HR: 0.139, 95.0% [CI]: 0.054-0.356 (p<0.001), albumin: HR: 0.946, 95.0% [CI]: 0.900-0.995 (p=0.032), tumor size: HR: 1.027, 95.0% [CI]: 1.106-1.318 (p<0.001), multiple tumors: HR: 2.027, 95.0% [CI]: 1.018-4.396 (p=0.024), tumor stage: HR: 0.562, 95.0% [CI]: 0.323-0.977 (p=0.041), MVI (M0): 0.083, 95.0% [CI]: 0.009-0.797 (p=0.031), metastasis: HR: 0.398, 95.0% [CI]: 0.168-0.941 (p=0.036)
According to the results of this analysis, which are summarized in Table 3, these factors can predict survival outcomes after resection.

3.3. Univariate and Multivariate Analysis of Predictors of Recurrence-Free Survival after Resection

The univariate Cox regression analysis model for RFS revealed that the following factors were significantly associated with lower RFS: age, sex, tumor number, tumor size, tumor stage, and the presence of portal vein thrombus. Table 4 shows the following predictive factors: age: HR: 1.056, 95% confidence interval [CI]: 1.035-1.078 (p<0.001); smoking: HR: 0.780, 95% [CI] 0.620-0.982, (p= 0.035); HBc-IgM: HR: 0.310, 95% [CI]: 0.111-0.866 (p=0.025); AFP: HR: 1.0, 95% [CI]: 1.0-1.0 (p=0.019); CA-125: HR: 1.006, 95% [CI]: 1.002-1.009 (p=0.005); tumor size: HR: 1.206, 95% [CI]: 1.138-1.279 (p<0.001); tumor number: HR: 5.883, 95% [CI]: 3.790-9.131 (p<0.001); and tumor stage: HR: 0.216, 95% [CI]: 0.143-0.326 (p<0.001), recurrence: HR: 0.044, 95.0% [CI]: 0.013-0.149 (p<0.001). Moreover, the multivariate Cox analysis revealed that only two factors were significant: HBc-IgM (HR: 0.170, 95.0% [CI]: 0.064–0.450 [p<0.001]) and recurrence (HR: 0.401, 95.0% [CI]: 0.282–0.571 [p<0.001]).
Otherwise, on the basis of this rationale, the variables were chosen for survival analysis. The proportionality assumption for the Cox model was tested via Pearson's chi-square test, as shown in Table 5, and RFS, as shown in Table 6.

3.4. Survival after Tumor Recurrence

The timing of recurrence is shown in Figure 4. The time interval between HCC resection and recurrence ranged from 2 to 84 months (median = 39 months). In 73 of 176 patients (41%) (p<0.001), recurrence developed within 84 months after resection. Figure 4 summarizes these results in a bar graph that shows a small peak.

3.5. Nomogram Predictive Model

By using the five predictive variables mentioned above, a nomogram for predicting 1-, 2-, 3-, and 5-year overall survival outcomes was developed (Figure 5). In the random forest analysis, initial resection treatment was the most important prognostic factor, followed by age, albumin level, tumor size, tumor number, and VTL (portal vein thrombosis and other cancer embolisms). The C-index of the nomogram for overall survival was 0.815 [95% CI, 0.769–0862 (P<0.001)] (Table 7). The internal calibration curves for predicting the 1-, 2-, 3-, and 5-year overall survival probabilities showed favorable calibration for predicting survival rates and correlated well with the actual survival rates at 1, 2, 3, and 5 years (Figure 6). Each variable was scored between 0 and 100 points. The time-dependent ROC curve nomograms that were used to predict 1-, 2-, 3- and 5-year OS indicated that operation-related prognostic factors had major impacts on patient prognosis. The 1–2–3 and 5-year AUCs for OS were 0.786–0.858–0.872 and 0.868, respectively (Figure 7). Additionally, the decision curve analysis (DCA) curves revealed that the nomogram had high prediction efficiency for OS in patients with HCC (Figure 8a-d).
The prognostic nomogram for 1-, 2-, 3- and 5-year RFS prediction in patients after resection is shown in Figure 9. Five variables were selected for the final predictive model: age, tumor stage, tumor size, tumor number, and VTL (portal vein thrombosis and other cancer embolisms). The C-index of the nomogram for RFS prediction was 0.80 [95% CI, 0.748–0.851

(P<0.001)] (Table 7). The calibration curves predicted the observed RFS probabilities for 1-, 2-, 3-, and 5-year RFS (Figure 10). These outcomes suggest that the nomogram has the potential to stratify HCC patients.
The RFS ROC curves for 1-, 2-, 3- and 5-year survival in the present study and the AUC values for 1-, 2-, 3- and 5-year survival were 0.840-, 0.869-, 0.888- and 0.883, respectively (Figure 11). Furthermore, DCA was performed, and the nomogram results revealed better net benefits with a wider range of thresholds (Figure 12a-d).

3.6. Independent Prognostic Factors for HCC

We performed multivariate Cox proportional regression OS analysis for 24 potential factors and identified six independent factors (Figure 13). The variables included age, albumin level, tumor size, tumor number, and portal vein thrombosis. Most variables were highly significant (p=0.05).
The multivariate Cox proportional regression RFS analysis clearly identified six potential factors in a forest plot (Figure 14). The variables included age, tumor stage, tumor size, tumor number, and portal vein thrombosis. Most of the factors were significant (p=0.05).

3.7. Risk Stratification for HCC with Survival Outcomes

At-risk classification systems for OS and RFS were developed according to the total scores of each patient produced by the nomograms, and the patients were divided into two groups. The results of the KM survival analysis with a log-rank test revealed differences in OS and RFS between the groups of patients with HCC (Figure 15). The OS group had a better prognosis than the RFS group did (p<0.001).

4. Discussion

Over the past few decades, liver resection has been the preferred method for treating HCC. Recently, it has been recognized as the gold standard treatment in the early and intermediate stages of HCC [20,21]. Tumor recurrence is one of the most significant poor prognostic factors for patients with HCC [22].
In our investigation, we identified 176 patients as candidates who underwent liver resection for HCC. We investigated pre- and postoperative predictive factors related to survival in patients with < 3 years of survival compared with those with > 3 years of survival.
The results of the model analysis predicted long-term OS and RFS and was validated with data from patients treated at our hospital.
Liver function is important for determining the primary treatment option and treatment results in patients with HCC. The serum albumin and bilirubin levels are reliable markers of a decline in liver function. The preoperative factors included in our model may aid in prognostication and shared decision-making for individual patients after resection of HCC. These factors include serum AFP, CA19-9, CA-125, HBsAg, HCV, postoperative vascular resection status, tumor stage (TNM), tumor size, tumor number, lymph node metastasis, and resection margin status.
The nomogram provides personalized predictions of patient prognosis after liver resection. However, several major problems remain. In the present analysis, we established a nomogram model of clinical characteristics and pathology for predicting survival outcomes in patients with HCC after resection on the basis of OS and RFS.
The nomogram demonstrated favorable accuracy when the C-index was calculated for OS (C-index 0.815, 95% CI 0.769–0.862; p<0.001) and RFS (C-index 0.80, 95% CI 0.748–0.851; p< 0.00). Moreover, its predictions for individual patient follow-up and treatment were excellent. Furthermore, the nomogram was able to predict OS and RFS in patients with HCC who had undergone various invasive therapies.
The nomogram was validated as an effective tool for predicting long-term results. Nonetheless, the current findings will need to be confirmed by larger prospective studies of different invasive treatments.

A recent study by Endo et al. [23] proposed a model to preoperatively predict overall survival among patients undergoing liver resection for primary HCC.
In our present work, age and tumor number were shown to play a role in the OS and RFS nomogram. Several studies have revealed that the age of the patient at the time of surgery and the presence of multiple tumors are crucial risk factors for recurrence, which is consistent with the findings of our present work [14,24]. Another study by Xiao et al. [25] reported that HCC patients have a poor prognosis because of metastasis and recurrence. There is a good association between tumor number and 1-year, 3-year and 5-year OS.

Our study revealed that for OS nomograms, tumor size is one of the anatomical factors associated with primary tumors. Previous studies have reported that pathological tumor size is a strong predictor of prognosis risk for patients with HCC [26,27].
A previous study by Chen et al. [28] noted that recurrent tumor factors, such as the tumor number, the size of the recurrent lesion, extrahepatic recurrence, and the development of recurrence within 12 months of primary resection, were independent adverse prognostic factors for survival after recurrence.

Our survival forest plot analysis revealed that PVT classification was another important factor affecting the OS and RFS results. Although various treatment options have been considered for PVT, the presence of PVT is associated with poor outcomes [29,30]. Another study by Mähringer et al. [31] reported that the extent of PVT and OS were significantly related.

Preprint

Moreover, our nomogram results, which are based on initial diagnosis and treatment, could be informative and helpful to both patients and physicians. Incorporating patient and treatment factors with tumor factors, such as tumor stage (TNM), PVT classification, albumin level, tumor size, and tumor number, improved the prediction of OS and RFS. Further studies are needed to validate the use of this nomogram in clinical practice.

However, there are several limitations in this study. First, it was a retrospective study conducted at a single center. A prospective study with a larger number of patients is needed for further validation of our results. Second, our prognostic prediction model clearly classified patients with resectable HCC with respect to their prognosis. The effect of this prognostic prediction model according to follow-up outcomes must be further investigated to establish its effectiveness for patients with resectable HCC. In the future, we will compare the OS of patients with recurrent HCC who are receiving various specific treatments.

5. Conclusion

In our study, we identified a cohort of patients with favorable oncological outcomes after resection by using a prognostic prediction model. Our findings may be applied to accurately predict prolonged life expectancy in patients with HCC who undergo resection. Predictive factors are essential for appropriate treatment selection given the increased number of patients with HCC who experience long-term survival following resection. Measuring liver function combined with AFP, CA125, and CA19-9 levels will be crucial for making better decisions regarding resection strategies in HCC patients.

Abbreviations

HCC: Hepatocellular carcinoma
OS: Overall survival
RFS: Recurrence-free survival
C-index: Concordance index
ROC curve: Receiver operating characteristic curve
AUC: Area under the receiver operating characteristic curve
DCA: Decision curve analysis
AFP: Alpha-fetoprotein
BMI: Body mass index
95.0% [CI]: 95.0% confidence interval

Author Contributions:

This work was designed by (XXX) and (XXX), Data collections done by (XXX), Informations analysis were done by (XXX) under revising by (XXX), All authors were wrote the this draft, All authors give final approval of the paper to be published.

Funding:

None

Institutional Review Board Statement:

This work were approved by (XXX) and gave PDF version of the the approval.

Informed Consent Statement:

Not applicable

Data Availability Statement:

All data generated and analyzed by the authors, Further inquires can be directed to corresponding author.

Acknowledgments:

None

Conflicts of Interest:

All authors declare that no any conflict of interest or financial required.

References

1. Villanueva, A. Hepatocellular carcinoma. *N. Engl. J. Med.* **2019**, *380*, 1450–1462; https://doi.org/10.1056/nejmra1713263.
2. Forner, A.; Llovet, J.M.; Bruix, J. Hepatocellular carcinoma. *Lancet* **2012**, *379*, 1245–1255; https://doi.org/10.1016/s0140-6736(11)61347-0.

Preprint

3. El-Serag, H.B. Hepatocellular carcinoma. *N. Engl. J. Med.* **2011**, *365*, 1118–1127; https://doi.org/10.1056/nejmra1001683.
4. Liao, K.; Yang, K.; Cao, L.; Lu, Y.; Zheng, B.; Li, X.; Wang, X.; Li, J.; Chen, J.; Zheng, S. Laparoscopic anatomical versus non-anatomical hepatectomy in the treatment of hepatocellular carcinoma: A randomised controlled trial. *Int. J. Surg.* **2022**, *102*, 106652; https://doi.org/10.1016/j.ijsu.2022.106652.
5. Chapman, W.C.; Klintmalm, G.; Hemming, A.; Vachharajani, N.; Doyle, M.B.M.; DeMatteo, R.; Zaydfudim, V.; Chung, H.; Cavaness, K.; Goldstein, R.; et al. Surgical treatment of hepatocellular carcinoma in North America: Can hepatic resection still be justified? *J. Am. Coll. Surg.* **2015**, *220*, 628–637; https://doi.org/10.1016/j.jamcollsurg.2014.12.030.
6. Moazzam, Z.; Lima, H.A.; Alaimo, L.; Endo, Y.; Shaikh, C.F.; Ratti, F.; Marques, H.P.; Soubrane, O.; Lam, V.; Poultsides, G.A.; et al. Impact of tumor burden score on timing and patterns of recurrence after curative-intent resection of hepatocellular carcinoma. *Surgery* **2022**, *172*, 1448–1455; https://doi.org/10.1016/j.surg.2022.07.019.
7. Shim, J.H.; Jun, M.-J.; Han, S.; Lee, Y.-J.; Lee, S.-G.; Kim, K.M.; Lim, Y.-S.; Lee, H.C. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. *Ann. Surg.* **2015**, *261*, 939–946; https://doi.org/10.1097/sla.0000000000000747.
8. Vogel, A.; Cervantes, A.; Chau, I.; Daniele, B.; Llovet, J.M.; Meyer, T.; Nault, J.C.; Neumann, U.; Ricke, J.; Sangro, B.; et al. Correction to: "Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up". *Ann. Oncol.* **2019**, *30*, 871–873; https://doi.org/10.1093/annonc/mdy510.
9. Gandhi, S.; Khubchandani, S.; Iyer, R. Quality of life and hepatocellular carcinoma. *J. Gastrointest. Oncol.* **2014**, *5*, 296–317; https://doi.org/10.3978/j.issn.2078-6891.2014.046.
10. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2021**, *71*, 209–249; https://doi.org/10.3322/caac.21660.
11. Amin, M.B.; Greene, F.L.; Edge, S.B.; Compton, C.C.; Gershenwald, J.E.; Brookland, R.K.; Meyer, L.; Gress, D.M.; Byrd, D.R.; Winchester, D.P. The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. *CA Cancer J. Clin.* **2017**, *67*, 93–99; https://doi.org/10.3322/caac.21388.
12. Reig, M.; Forner, A.; Rimola, J.; Ferrer-Fàbrega, J.; Burrel, M.; Garcia-Criado, Á.; Kelley, R.K.; Galle, P.R.; Mazzaferro, V.; Salem, R.; et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J. Hepatol.* **2022**, *76*, 681–693; https://doi.org/10.1016/j.jhep.2021.11.018.
13. Kudo, M.; Chung, H.; Osaki, Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). *J. Gastroenterol.* **2003**, *38*, 207–215; https://doi.org/10.1007/s005350300038.
14. Xu, X.-F.; Xing, H.; Han, J.; Li, Z.-L.; Lau, W.-Y.; Zhou, Y.-H.; Gu, W.-M.; Wang, H.; Chen, T.-H.; Zeng, Y.-Y.; et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: A multicenter study from China. *JAMA Surg.* **2019**, *154*, 209–217; https://doi.org/10.1001/jamasurg.2018.4334.
15. Tranchart, H.; Chirica, M.; Sepulveda, A.; Massault, P.P.; Conti, F.; Scatton, O.; Soubrane, O. Long-term outcomes following aggressive management of recurrent hepatocellular carcinoma after upfront liver resection. *World J. Surg.* **2012**, *36*, 2684–2691; https://doi.org/10.1007/s00268-012-1723-9.
16. Li, Y.; Xia, Y.; Li, J.; Wu, D.; Wan, X.; Wang, K.; Wu, M.; Liu, J.; Lau, W.Y.; Shen, F. Prognostic nomograms for pre- and postoperative predictions of long-term survival for patients who underwent liver resection for huge hepatocellular carcinoma. *J. Am. Coll. Surg.* **2015**, *221*, 962–974.e964; https://doi.org/10.1016/j.jamcollsurg.2015.08.003.
17. Zhang, X.-P.; Chen, Z.-H.; Zhou, T.-F.; Li, L.-Q.; Chen, M.-S.; Wen, T.-F.; Shi, J.; Guo, W.-X.; Wu, M.-C.; Lau, W.Y.; et al. A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection: A large-scale, multicenter study. *Eur. J. Surg. Oncol.* **2019**, *45*, 1644–1651; https://doi.org/10.1016/j.ejso.2019.03.043.
18. Takuma, Y.; Shota, I.; Miyatake, H.; Uematsu, S.; Okamoto, R.; Araki, Y.; Takabatake, H.; Morimoto, Y.; Yamamoto, H. Nomograms to predict the disease-free survival and overall survival after radiofrequency ablation for hepatocellular carcinoma. *Intern. Med.* **2018**, *57*, 457–468; https://doi.org/10.2169/internalmedicine.9064-17.
19. Cho, C.S.; Gonen, M.; Shia, J.; Kattan, M.W.; Klimstra, D.S.; Jarnagin, W.R.; D'Angelica, M.I.; Blumgart, L.H.; DeMatteo, R.P. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. *J. Am. Coll. Surg.* **2008**, *206*, 281–291; https://doi.org/10.1016/j.jamcollsurg.2007.07.031.
20. Troisi, R.I.; Berardi, G.; Morise, Z.; Cipriani, F.; Ariizumi, S.; Sposito, C.; Panetta, V.; Simonelli, I.; Kim, S.; Goh, B.K.P.; et al. Laparoscopic and open liver resection for hepatocellular carcinoma with child-pugh B cirrhosis: Multicentre propensity score-matched study. *Br. J. Surg.* **2021**, *108*, 196–204; https://doi.org/10.1093/bjs/znaa041.
21. Nguyen-Khac, V.; Brustia, R.; Rhaiem, R.; Regnault, H.; Sessa, A.; Mule, S.; Duvoux, C.; Laurent, A.; Leroy, V.; Calderaro, J.; et al. Liver resection for single large hepatocellular carcinoma: A prognostic factors study. *Ann. Hepatol.* **2022**, *27*, 100739; https://doi.org/10.1016/j.aohep.2022.100739.
22. Rodríguez-Perálvarez, M.; Luong, T.V.; Andreana, L.; Meyer, T.; Dhillon, A.P.; Burroughs, A.K. A systematic review of microvascular invasion in hepatocellular carcinoma: Diagnostic and prognostic variability. *Ann. Surg. Oncol.* **2012**, *20*, 325–339; https://doi.org/10.1245/s10434-012-2513-1.

23. Endo, Y.; Lima, H.A.; Alaimo, L.; Moazzam, Z.; Brown, Z.; Shaikh, C.F.; Ratti, F.; Marques, H.P.; Soubrane, O.; Lam, V.; et al. Preoperative risk score (PreopScore) to predict overall survival after resection for hepatocellular carcinoma. *HPB* **2023**, *25*, 353–362; https://doi.org/10.1016/j.hpb.2022.12.009.
24. Lei, Z.; Li, J.; Wu, D.; Xia, Y.; Wang, Q.; Si, A.; Wang, K.; Wan, X.; Lau, W.Y.; Wu, M.; et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus–related hepatocellular carcinoma within the milan criteria. *JAMA Surg.* **2016**, *151*, 356–363; https://doi.org/10.1001/jamasurg.2015.4257.
25. Xiao, Y.B.; Zhang, B.; Wu, Y.L. Radiofrequency ablation versus hepatic resection for breast cancer liver metastasis: A systematic review and meta-analysis. *J. Zhejiang Univ. Sci. B* **2018**, *19*, 829–843; https://doi.org/10.1631/jzus.B1700516.
26. Chan, A.W.H.; Zhong, J.; Berhane, S.; Toyoda, H.; Cucchetti, A.; Shi, K.; Tada, T.; Chong, C.C.N.; Xiang, B.-D.; Li, L.-Q.; et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. *J. Hepatol.* **2018**, *69*, 1284–1293; https://doi.org/10.1016/j.jhep.2018.08.027.
27. Zhang, L.-X.; Luo, P.-Q.; Chen, L.; Song, D.-D.; Xu, A.M.; Xu, P.; Xu, J. Model to predict overall survival in patients with hepatocellular carcinoma after curative hepatectomy. *Front. Oncol.* **2020**, *10*, 537526; https://doi.org/10.3389/fonc.2020.537526.
28. Chen, W.T.; Chau, G.Y.; Lui, W.Y.; Tsay, S.H.; King, K.L.; Loong, C.C.; Wu, C.W. Recurrent hepatocellular carcinoma after hepatic resection: Prognostic factors and long-term outcome. *Eur. J. Surg. Oncol.* **2004**, *30*, 414–420; https://doi.org/10.1016/j.ejso.2004.01.013.
29. Choe, W.H. Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus? *J. Liver Cancer* **2022**, *22*, 1–3; https://doi.org/10.17998/jlc.2022.03.15.
30. Zhang, F.; Lu, C.-D.; Zhang, X.-P.; Chen, Z.-H.; Zhong, C.-Q.; Hu, Y.-R.; Wei, X.-B.; Zhou, B.; Wang, K.; Chai, Z.-T.; et al. The impact of portal vein tumor thrombus on long-term survival after liver resection for primary hepatic malignancy. *HPB* **2020**, *22*, 1025–1033; https://doi.org/10.1016/j.hpb.2019.10.2439.
31. Mähringer-Kunz, A.; Steinle, V.; Düber, C.; Weinmann, A.; Koch, S.; Schmidtmann, I.; Schotten, S.; Hinrichs, J.B.; Graafen, D.; dos Santos, D.P.; et al. Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse? *Liver Int.* **2019**, *39*, 324–331; https://doi.org/10.1111/liv.13988.

Preprint

Figure Legends

Figure 1. Patient selection flow diagram. Inclusion and exclusion criteria for evaluating prognostic factors after surgery in patients with HCC. We focused on two subsets., i.e., individuals who survived 3 years or less (short-term survivors) and those who survived 3 years or more (long-term survivors). Four patients were excluded. Results: Forty-eight short-term patients and 128 long-term patients were enrolled in this clinical study.

Figure 2. Kaplan–Meier curve showing the overall survival (OS) rate of the entire cohort of patients in the study.

Figure 3. Kaplan–Meier curve showing the recurrence-free survival (RFS) rate of the entire cohort of patients included in the study.

Figure 4. Time to recurrence after resection.

Figure 5. Nomogram model for predicting the overall survival of hepatocellular carcinoma patients.

Figure 6. The overall survival calibration curve for predicting patient survival at 1 year, 2 years, 3 years, and 5 years.

Figure 7. Overall survival ROC curves of the nomograms for 1-, 2-, 3- and 5-year OS.

Figure 8. Decision curve analysis (DCA) of overall survival (OS) [(**a**) 1 year; (**b**) 2 years; (**c**) 3 years; (**d**) 5 years].

Figure 9. Nomogram model for predicting recurrence-free survival of hepatocellular carcinoma patients.

Figure 10. Recurrence-free survival calibration curve for predicting patient survival at 1 year, 2 years, 3 years, and 5 years.

Figure 11. Recurrence-free survival ROC curves of the nomograms for 1-, 2-, 3- and 5-year RFS.

Preprint

Preprint

Predictive factors of improved postoperative results after surgery for patients with hepatocellular carcinoma: A retrospective study

GOAL



Nomogram predicted long-term overall survival (OS) for HCC patients.

176 Patients

NOMOGRAM

Age | **Albumin**

Tumor Size | VTL | **Tumor Number**

Nomogram of OS (C-index 0.815)

Preprint

Table 1: Baseline patient characteristics outcomes.

Variables	Short term Survival ≤ 3 years Survivors n=48	Long term Survival > 3 years Survivors n=128	P value
Age (years)	71.0 ± 11.6	64.3 ± 11.9	0.002*
Gender, **n (%)**			0.381
Male	43 (89.6)	108 (84.4)	
Female	5 (10.4)	20 (15.6)	
BMI (kg/m^2)	22.4 ± 3.0	23.8 ± 3.2	0.016*
Alcohol n (%)			0.613
No	28 (58.3%)	80 (62.5%)	
Yes	20 (41.7%)	48 (37.5%)	
Smoking n (%)			0.042*
No	21 (43.8%)	78 (60.9%)	
Yes	27 (56.2%)	50 (39.1%)	
Liver Cirrhosis n (%)			0.651
No	14 (29.2)	33 (25.8)	
Yes	34 (70.8)	95 (74.2)	
Hypertension n (%)			0.945
No	35 (72.9%)	94 (73.4%)	
Yes	13 (27.1%)	34 (26.6%)	
Diabetes n (%)	42 (87.5%)	117 (91.4%)	0.437
No	6 (12.5%)	11 (8.6%)	
Yes			
HBV-PreS2Ag, n (%)			0.074
Negative	16 (33.3%)	62 (48.4%)	
Positive	32 (66.7%)	66 (51.6%)	
HBc-IgM, n (%)			0.987
Negative	46 (95.8%)	128 (100%)	
Positive	2 (4.2%)	0 (0%)	
HBc-IgG, n (%)			0.728
Negative	2 (4.2%)	7 (5.5%)	
Positive	46 (95.8%)	121 (94.5%)	
HBeAg, n (%)			0.66
Negative	36 (75.0)	100 (78.1)	

Preprint

Positive	12 (25.0)	28 (21.9)	
HBsAb, n (%)			0.285
Negative	8 (16.7)	31 (24.2)	
Positive	40 (83.3)	97 (75.8)	
HCV, n (%)			0.253
Negative	48 (100)	126 (98.4)	
Positive	0 (0)	2 (1.6)	
Tumor stage, n (%)			<0.001*
I	16 (33.3%)	89 (69.5%)	
II	15 (31.2%)	27 (21.1%)	
III	3 (6.2%)	6 (4.7%)	
IV	14 (29.2%)	6 (4.7%)	
Albumin (g/L)	37.3 ± 6.4	41.2 ± 6.8	0.001*
Total Bilirubin (μmoI/L)	22.4 ± 33.2	19.9 ± 21.9	0.573
Direct Bilirubin (μmoI/L)	13.4 ± 12.6	13.0 ± 8.2	0.806
CA19-9 (U/ml)	71.9 ± 184.2	26.8 ± 37.8	0.07
CA-125 (U/ml)	32.6 ± 66.2	15.2 ± 15.5	0.026*
AFP (ng/ml)	65.11 (7.50-905.90)	20.75 (4.85-267.67)	0.090
CEA (ng/ml)	3.3 ± 1.8	2.8 ± 1.7	0.086
Ferritin (ng/ml)	380.6 ± 342.4	328.2 ± 264.9	0.287
OS, months	13.0 (4.0-20.3)	72.0 (60.0-82.0)	<0.001*
OS, months	6.0 (2.0-11.5)	59.5 (33.8-74.5)	<0.001*

Preprint

Table 2: Histopathological findings and resection outcomes

Variables	Short term Survival ≤ 3 years Survivors n=48	Middle term Survival > 3 years Survivors n=128	P value
Tumor size, cm			0.001
≤5.0	23 (47.9)	99 (77.3)	
5.1-9.9	17 (35.5)	23 (18.0)	
≥10.0	8 (16.6)	6 (4.7)	
Tumor Number	1.6 ± 0.5	1.1 ± 0.3	<0.001
Recurrence, n (%)			
No	17 (35.4)	86 (67.2)	<0.001
Yes	31 (64.6)	42 (32.8)	
Hospital stay (days)	19.0 (13.3-24.8)	14.0 (10.0-20.0)	0.005
MVI grade n %			0.992
No	45 (93.8)	127 (99.2)	
Yes	3 (6.3)	1 (0.8)	
Resection margin, n %			0.813
Negative	47 (97.9)	126 (98.4)	
Positive	1 (2.1)	2 (1.6)	
Type of resection, n (%)			0.715
Bilobar	2 (4.2)	7 (5.5)	
Left	14 (29.2)	33 (25.8)	
Right	32 (66.7)	88 (68.8)	
Lymph node metastasis, n (%)			0.321
No	46 (95.8)	126 (98.4)	
Yes	2 (4.2)	2 (1.6)	
Metastasis n (%)			0.067
No	45 (93.8%)	127 (99.2%)	
Yes	3 (6.2%)	1 (0.8%)	
Vascular tumors of the liver (VTL)			
Portal vein thrombus n (%)	17 (35.4)	12 (9.4)	<0.001
Other Cancers embolism n (%)	8 (16.7)	14 (10.9)	0.063

Preprint

Table 3 : Univariate and multivariate Cox regression analyses of predictive factors for overall survival (OS)

Variable	Reference	Univariate analysis HR (95% CI)	P value	Multivariate analysis HR (95% CI)	P value
Age (years)	≤ 60y, > 60y	1.059 (1.037-1.083)	<0.001*	1.043 (1.018-1.069)	<0.001*
Gender	Male vs Female	0.511 (0.221-1.180)	0.116		
BMI	≤ 24.0, > 24.0	0.917 (0.852-0.987)	0.022*	0.884 (0.807-0.969)	0.009*
Smoking	Absent vs Present	0.633 (0.397-1.010)	0.055		
Alcohol	Absent vs Present	0.9 (0.498-1.272)	0.340		
HBV	Absent vs Present	0.883 (0.499-1.562)	0.669		
HCV	Absent vs Present	4.534 (0.052-392.0368)	0.507		
HBc-IgM	Absent vs Present	0.238 (0.112-0.504)	<0.001*	0.139 (0.054-0.356)	<0.001*
Hypertension	Absent vs Present	0.634 (0.389-1.036)	0.069		
Diabetes	Absent vs Present	0.960 (0.440-2.095)	0.917		
Liver Cirrhosis	Absent vs Present	1.078 (0.836-1.392)	0.562		
Albimin	≤ 40, > 40	0.931 (0.892-0.972)	0.001*	0.946 (0.900-0.995)	0.032*
AFP (ng/mL)	≤ 250, > 250	1 (1-1)	0.059		
CA19-9	≤ 25, > 25	1.003 (1.002-1.005)	<0.001*	0.996 (0.993-1)	0.061
CA-125	≤ 25, > 25	1.005 (1.001-1.008)	0.011*	1.001 (0.996-1.005)	0.813
Tumor size (cm)	≤ 5.0 cm, > 5.0 cm	1.238 (1.172-1.308)	<0.001*	1.027 (1.106-1.318)	<0.001*
Tumors number	Absent vs Present	4.294 (2.750-6.705)	<0.001*	2.027 (1.018-4.396)	0.024*
Tumor stage	I,II,III,IV	2.76 (0.273-2.132)	<0.001*	0.562 (0.323-0.977)	0.041*
Resection margin	Negative/Positive	0.785 (0.388-1.591)	0.502		
Recurrence	Absent vs Present	0.600 (0..472-0.762)	<0.001*	1.107 (0.746-1.643)	0.612
MVI			0.002*		<0.001*
	M0	1.307 (0.181-9.429)		0.083 (0.009-0.797)	0.031*
	M1/M3	17.107 (2.189-133.6)		5.577 (0.272-114.547)	0.265
Lymph node metastasis	Absent vs Present	0.701 (0.346-1.417)	0.322		
Metastasis	Absent vs Present	0.510 (0.285-0.912)	0.023*	0.398 (0.168-0.941)	0.036*
Portal vein thrombus	Absent vs Present	0.38 (0.381-1.156)	0.703	1.63 (0.455- 0.475)	0.1030

Preprint

Table 4 : Univariable and multivariate Cox regression results Prognostic factors were associated with Recurrence-free survival (RFS).

Variable	Reference	Univariate analysis HR (95% CI)	P value	Multivariate analysis HR (95% CI)	P value
Age (years)	≤ 60y, > 60y	1.056 (1.035-1.078)	<0.001*	0.995 (0.971-1.020)	0.707
Gender	Male vs Female	0.724 (0.490-1.068)	0.104		
BMI	≤ 24.0, > 24.0	0.992 (0.924-11065)	0.827		
Smoking	Absent vs Present	0.780 (0.620-0.982)	0.035*	1.017 (0.788-1.313)	0.895
Alcohol	Absent vs Present	0.958 (0.758-1.211)	0.721		
HBV	Absent vs Present	1.272 (0.911-1.776)	0.157		
HCV	Absent vs Present	0.454 (0.074-276.83)	0.471		
HBc-IgM	Absent vs Present	0.310 (0.111-0.866)	0.025*	0.170 (0.064-0.450)	<0.001*
Hypertension	Absent vs Present	0.942 (0.731-1.214)	0.644		
Diabetes	Absent vs Present	1.005 (0.681-1.484)	0.980		
Liver Cirrhosis	Absent vs Present	0.991 (0.763-1.287)	0.943		
Albimin	≤ 40.0 > 40.0	0.964 (0.926-1.003)	0.070		
AFP (ng/mL)	≤ 25.0 > 25.0	1 (1-1)	0.019*		
CA19-9	≤ 25.0 > 25.0	1.002 (0.999-1.004)	0.309		
CA-125	≤ 25.0 > 25.0	1.006 (1.002-1.009)	0.005*	1.004 (0.999-1.009)	0.138
Tumor size (cm)	≤ 5.0 cm, > 5.0 cm	1.206 (1.138-1.279)	<0.001*	1.007 (0.930-1.091)	0.859
Tumor number	Absent vs Present	5.883 (3.790-9.131)	<0.001*	1.172 (0.598-2.297)	0.644
Tumor stage	I,II,III,IV	0.216 (0.143-0.326)	<0.001*	0.774 (0.460-1.303)	0.335
Resection margin	Negative/Positive	1.111 (0.414-2.983)	0.834	1.010 (0.553-1.846)	0.974
Recurrence	Absent vs Present	0.044 (0.013-0.149)	<0.001*	0.401 (0.282-0.571)	<0.001*
Lymph node metastasis	Absent vs Present	0.772 (0.382-1.560)	0.471		
Metastasis	Absent vs Present	0.577 (0.285-1.167)	0.126		

Preprint

Table 5: Assessment of the risk proportionality assumption by the Cox model of overall survival

	Univariate Cox model		Multivariate Cox model	
Variables	Qui-Square	p-Value*	Qui-Square	p-Value*
Age	23.5053	<0.001	19.91799	<0.001
BMI	0.1769	0.67401		
Albumin	12.0677	0.00051	11.3691	0.00075
CA125	1.3878	0.23879		
Tumor Size	0.6817	0.40899	0.33671	0.56173
Tumor Numbers	0.1014	0.75014	0.00139	0.97022
Smoking	0.0598	0.80683		
Tumor Stage	5.1826	0.1589		
Recurrence	7.3856	0.00657		
Portal Vein Thrombosis	1.0079	0.60413	0.88675	0.64187

*Significant if $p<0.05$ based on Pearson's chi-square test.

Preprint

Table 6: Assessment of the risk proportionality assumption by the Cox model of recurrence-free survival.

	Univariate Cox model		Multivariate Cox model	
Variables	Qui-Square	p-Value*	Qui-Square	p-Value*
Age	0.1923	0.661	4.485	0.034
Albumin	0.6972	0.404		
Tumor Size	2.4729	0.116	1.038	0.308
Tumor Numbers	0.5198	0.471	0.323	0.570
Smoking	2.1657	0.141		
HBV-PreS2Ag	5.5375	0.019		
Portal Vein Thrombosis	2.7783	0.249	2.733	0.255
Tumor Stage	0.0817	0.775	1.924	0.165
Recurrence	0.0131	0.909		

*Significant if $p<0.05$ based on Pearson's chi-square test.

Preprint

Table 7: Performance C-index nomogram model of OS and RFS

	C-index	95% CI	P value
Nomogram of OS	0.815	0.769-0.862	<0.001
Nomogram of RFS	0.80	0.748-0.851	<0.001

OS: overall survival . RFS: recurrence-free survival . CI: confidence interval

Preprint



Figure 1

Preprint



Preprint

Figure 2



Figure 3

Preprint



Figure 4

Preprint



Figure 5

Preprint



Preprint

Figure 6



Figure 7

Preprint



Preprint

Figure 8



Preprint

Figure 8 B


0.3
0.2
0.1
0.0
Net Benefit
All
None
3-Year Survival probability Nomogram(OS)
0%
25%
50%
75%
100%
Risk Threshold
Preprint


All
None
5-Year Survival probability Nomogram(OS)
Net Benefit
0.4
0.3
0.2
0.1
0.0
0%
25%
50%
75%
100%
Risk Threshold

Preprint


Points
0 10 20 30 40 50 60 70 80 90 100
Tumor Size
0 2 4 6 8 10 12 14 16
Tumor Stage (TNM)
1 2 3 4
Tumor Numbers
1 2 3
VTL
No Other Cancer Embolisms Portal Vein Thrombosis
Age
35 40 45 50 55 60 65 70 75 80 85 90
Total Points
0 20 40 60 80 100 120 140 160 180 200 220 240 260
1−year HCC RFS probability
0.9 0.80 0.70 0.6 0.5 0.4 0.3 0.2 0.1
2−year HCC RFS probability
0.9 0.80 0.70 0.6 0.5 0.4 0.3 0.2 0.1
3−year HCC RFS probability
0.9 0.80 0.70 0.6 0.5 0.4 0.3 0.2 0.1
5−year HCC RFS probability
0.9 0.80 0.70 0.6 0.5 0.4 0.3 0.2 0.1

Preprint


(A)
Actual 1−year RFS
Nomogram predicted 1−year RFS
(B)
Actual 2−year RFS
Nomogram predicted 2−year RFS
(C)
Actual 3−year RFS
Nomogram predicted 3−year RFS
(D)
Actual 5−year RFS
Nomogram predicted 5−year RFS
0.0
0.2
0.4
0.6
0.8
1.0

Preprint


Sensitivity
1−Specificity
0.0
0.2
0.4
0.6
0.8
1.0
1−year RFS AUC (95%CI) = 0.840 (0.770 − 0.911)
2−year RFS AUC (95%CI) = 0.869 (0.808 − 0.930)
3−year RFS AUC (95%CI) = 0.888 (0.833 − 0.942)
5−year RFS AUC (95%CI) = 0.883 (0.826 − 0.940)

Preprint


All
None
1-Year Survival probability Nomogram(RFS)
Net Benefit
0.3
0.2
0.1
0.0
0%
25%
50%
75%
100%
Risk Threshold

Preprint


All
None
2-Year Survival probability Nomogram(RFS)
Net Benefit
0.4
0.3
0.2
0.1
0.0
0%
25%
50%
75%
100%
Risk Threshold

Preprint


0.4
0.3
0.2
0.1
0.0
Net Benefit
All
None
3-Year Survival probability Nomogram(RFS)
0%
25%
50%
75%
100%
Risk Threshold

Preprint


All
None
5-Year Survival probability Nomogram(RFS)
Net Benefit
0.5
0.4
0.3
0.2
0.1
0.0
0%
25%
50%
75%
100%
Risk Threshold

Preprint


Variabl
Hazard Ratio(95%CI)
P value
VTL(Other Cancer Embolisms)
0.68(0.33~1.38)
0.282
VTL(portal vein thrombosis)
2.39(1.35~4.24)
0.003
Albumin
0.95(0.9~0.99)
0.014
Tumor Size
1.17(1.09~1.26)
<0.001
Tumors Numbers
1.73(1~3.01)
0.051
Age
1.04(1.02~1.06)
<0.001
0
0.5
1
1.5
2
2.5
3
3.5
4
Hazard Ratio

Preprint


Variabl
Hazard Ratio(95%CI)
P value
VTL (Other Cancer Embolisms) 1.08(0.53~2.21) 0.828
VTL (portal vein thrombosis) 2.13(1.15~3.94) 0.016
Tumor Size 1.09(1.01~1.17) 0.023
Tuomr Stage (TNM) 1.35(1.07~1.71) 0.012
Tumor Numbers 2.11(1.19~3.73) 0.01
Age 1.04(1.01~1.06) 0.002
0
0.5
1
1.5
2
2.5
3
3.5
4
Hazard Ratio

Preprint



Number at risk

OS	176	158	140	132	126	121	98	69	44
RFS	176	139	116	105	96	88	69	42	29

Preprint